Aug 13, 2020
KAHR Medical to Present at Oppenheimer's Private Life Sciences Company Call Series
Aug 12, 2020
KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors
Apr 09, 2020
Vigeo Therapeutics Doses First Patients in Expansion Phase of its 1b/2 Study Investigating VT1021 in Patients with CD36 Expressing Cancers
Mar 25, 2020
Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China
Feb 25, 2020
KAHR Medical Raises $18 Million in Private Funding Round
Jan 07, 2020
Beta Lifescience Announces the Online Availability of Quality Immune Checkpoint Proteins for Scientific Discoveries
Sep 23, 2019
I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Multiple Cancer Types
Sep 09, 2019
KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients
Jul 13, 2019
I-Mab Announces IND Approval for Its Proprietary TJC4, A Potentially Differentiated CD47 Antibody, to Initiate Clinical Trials in China
Jun 25, 2019
I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States
May 31, 2019
Targeting the CD47-SIRPA Axis in Oncology, 2019 - Identify, Prioritize, and Lead Scientific Assessment of Opportunities and Competition
Mar 18, 2019
Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody in the U.S.
Jan 28, 2019
I-Mab Receives IND Approval from the US FDA to Initiate Clinical Trials for Its Proprietary TJC4, a Potential Global Best-in-Class Anti-CD47 Monoclonal Antibody
Jan 14, 2019
Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody
Dec 04, 2018
Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-OX40 Monoclonal Antibody IBI101
Sep 29, 2018
Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-CD47 Monoclonal Antibody IBI-188
Jun 03, 2018
Forty Seven, Inc. Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphoma
May 17, 2018
Forty Seven, Inc. to Present Preliminary Data from its Ongoing Phase 1 Clinical Trial of 5F9 in Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association (EHA)
May 16, 2018
Forty Seven, Inc. to Present Clinical Data on 5F9, its First-in-Class CD47 Antibody, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 03, 2018
Forty Seven, Inc. Appoints Ann D. Rhoads as Chief Financial Officer